HEALTH

SmithKline to Cancel Heart Drug Trials: The pharmaceutical company said the experimental drug has proven effective enough to cancel the two late-stage clinical trials and allow patients to take the drug as regular therapy under medical supervision. London-based SmithKline Beecham said the trials proved that the drug, called carvedilol, has an “unexpectedly strong effect” in reducing deaths from congestive heart failure. It said the move was recommended by the Data and Safety Monitoring Board, a four-member independent commission that advises doctors on medical matters.